Head to Head Survey: BioLargo (BLGO) and Its Rivals

BioLargo (NASDAQ:BLGO) is one of 34 publicly-traded companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its competitors? We will compare BioLargo to similar businesses based on the strength of its analyst recommendations, profitability, institutional ownership, earnings, valuation, dividends and risk.

Profitability

This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-568.74%	5.73%	-0.15%

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioLargo and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1274	1591	46	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 4.94%. Given BioLargo’s competitors higher possible upside, analysts clearly believe BioLargo has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares BioLargo and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.00
BioLargo Competitors	$6.63 billion	$206.77 million	67.66

BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

BioLargo has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.78, meaning that their average share price is 78% more volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioLargo competitors beat BioLargo on 8 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.